WallStSmart

ResMed Inc (RMD)vsSharps Technology Inc (STSS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 2423624% more annual revenue ($5.40B vs $222,720). RMD leads profitability with a 27.5% profit margin vs 0.0%. RMD earns a higher WallStSmart Score of 70/100 (B).

RMD

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 8.7Quality: 8.3
Piotroski: 6/9Altman Z: 4.34

STSS

Avoid

25

out of 100

Grade: F

Growth: 4.3Profit: 2.5Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

RMDUndervalued (+14.4%)

Margin of Safety

+14.4%

Fair Value

$303.30

Current Price

$226.31

$76.99 discount

UndervaluedFair: $303.30Overvalued

Intrinsic value data unavailable for STSS.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.7%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
27.5%9/10

Keeps 28 of every $100 in revenue as profit

STSS1 strengths · Avg: 10.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Areas to Watch

RMD0 concerns · Avg: 0/10

No major concerns identified

STSS4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$90.61M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.

Bull Case : STSS

The strongest argument for STSS centers on Price/Book.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Bear Case : STSS

The primary concerns for STSS are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

RMD profiles as a mature stock while STSS is a value play — different risk/reward profiles.

STSS carries more volatility with a beta of 2.13 — expect wider price swings.

RMD is growing revenue faster at 11.0% — sustainability is the question.

RMD generates stronger free cash flow (311M), providing more financial flexibility.

Bottom Line

RMD scores higher overall (70/100 vs 25/100), backed by strong 27.5% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Sharps Technology Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Sharps Technology Inc., a medical device company, researches, designs, develops, manufactures, distributes and sells safety syringes in the United States. The company is headquartered in Melville, New York.

Want to dig deeper into these stocks?